National Bank of Canada
HRTX icon

National Bank of Canada’s Heron Therapeutics HRTX Stock Holding History

National Bank of Canada’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$188 – 2814
2023
Q4 		$188 Sell
100
-500
-83% -$551 ﹤0.01% 2638
2023
Q3 		$586 Hold
600
– – ﹤0.01% 2640
2023
Q2 		$690 Hold
600
– – ﹤0.01% 2590
2023
Q1 		$906 Hold
600
– – ﹤0.01% 2543
2022
Q4 		$1.49K Hold
600
– – ﹤0.01% 2536
2022
Q3 		$3K Hold
600
– – ﹤0.01% 2443
2022
Q2 		$2K Hold
600
– – ﹤0.01% 2594
2022
Q1 		$3K Hold
600
– – ﹤0.01% 2645
2021
Q4 		$5K Buy
+600
New +$6.13K ﹤0.01% 2531

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

National Bank of Canada's HRTX Position: Q1 2024 in Review

National Bank of Canada sold out of Heron Therapeutics (HRTX) in Q1 2024, closing a stake of 100 shares — an estimated $188 sold.

National Bank of Canada first reported a position in HRTX in Q4 2021 and held it in 9 quarters. The position peaked at $5K in Q4 2021. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.

  • National Bank of Canada reported no remaining Heron Therapeutics position as of Q1 2024 after selling out during the quarter.
  • National Bank of Canada sold 100 Heron Therapeutics shares in Q1 2024, an estimated $188.
  • National Bank of Canada first reported a position in Heron Therapeutics in Q4 2021 and held it in 9 quarters.
  • National Bank of Canada's Heron Therapeutics position peaked at $5K in Q4 2021.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.

Based on National Bank of Canada's 13F filing for Q1 2024, filed 13 May 2024.